Sol Gel Technologies Ltd at Jefferies Healthcare Conference Transcript
[Good evening] and welcome to the Jefferies 2022 Healthcare Conference. It's my great pleasure to introduce Alon Seri-Levy, the CEO of Sol-Gel Therapeutics; and Gilad Mamlok, the CFO. Doc, I'll hand it to you.
Thank you very much. Good morning and thank you for coming to listen to my talk about Sol-Gel and about our new drugs, EPSOLAY and TWYNEO, which was just approved by the FDA. Together with me is Gilad Mamlok, our CFO, and the two of us would be delighted to answer your questions at the end of my talk. But before I start, I would like you to pay attention to this cautionary note on forward-looking statements.
It is rare that a company the size of Sol-Gel gets two NDA approvals within less than a year. In July of last year, we received FDA approval for TWYNEO. The first and only FDA approved fixed-dose combination drug of tretinoin and benzoyl peroxide for the treatment of acne vulgaris in adults and pediatric patients, nine years of age and older.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
